Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
Status:
Completed
Trial end date:
2017-09-21
Target enrollment:
Participant gender:
Summary
Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate
efficacy and safety of a 12-months treatment with deferiprone (DFP) at dose of 75-100
mg/kg/day versus deferasirox (DFX) at dose of 20-40 mg/kg/day in paediatric patients (1 month
< 18 years old) affected by hereditary haemoglobinopathies and requiring frequent
transfusions and chelation.
Phase:
Phase 3
Details
Lead Sponsor:
Consorzio per Valutazioni Biologiche e Farmacologiche